Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
7512 results:

  • 1. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Bioinformatics-driven discovery of novel egfr kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
    Radwan AA; Alanazi F; Al-Dhfyan A
    PLoS One; 2024; 19(4):e0298326. PubMed ID: 38625872
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
    Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
    Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A Path to Persistence after egfr Inhibition.
    Rumde PH; Burns TF
    Cancer Res; 2024 Apr; 84(8):1188-1190. PubMed ID: 38616658
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mobocertinib in Patients with egfr Exon 20 Insertion-Positive Non-small cell lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
    Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. egfr degraders in non-small-cell lung cancer: Breakthrough and unresolved issue.
    Shen J; Chen L; Liu J; Li A; Zheng L; Chen S; Li Y
    Chem Biol Drug Des; 2024 Apr; 103(4):e14517. PubMed ID: 38610074
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Nicotinamide in Combination with egfr-TKIs for the treatment of Stage IV lung Adenocarcinoma with egfr Mutations: A Randomized Double-Blind (Phase IIb) Trial.
    Oh HJ; Bae SC; Oh IJ; Park CK; Jung KM; Kim DM; Lee JW; Kang CK; Park IY; Kim YC
    Clin Cancer Res; 2024 Apr; 30(8):1478-1487. PubMed ID: 38593249
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
    Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [First-line treatment with Furmonertinib Mesylate in lung Adenocarcinoma Patient 
with egfr Exon 20 Insertion Mutantion].
    Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
    Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
    Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis.
    Fukuda Y; Uchida Y; Ando K; Manabe R; Tanaka A; Sagara H
    Respir Investig; 2024 May; 62(3):481-487. PubMed ID: 38569441
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in egfr-mutated non-small cell lung cancer.
    Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
    J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting egfr degradation by autophagosome degraders.
    Zhu Z; Li J; Shen S; Al-Furas H; Li S; Tong Y; Li Y; Zeng Y; Feng Q; Chen K; Ma N; Zhou F; Zhang Z; Li Z; Pang J; Ding K; Xu F
    Eur J Med Chem; 2024 Apr; 270():116345. PubMed ID: 38564826
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. New treatment Options for Patients With Oncogene-Addicted Non-small cell lung cancer Focusing on
    Saw SPL; Le X; Hendriks LEL; Remon J
    Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Association of systemic inflammatory markers with prognosis in erlotinib-treated egfr-mutant non-small cell lung cancer.
    Yetişir AE; Paydaş S; Büyükşimşek M; Oğul A; Kolsuz İ; Kıdı MM
    J Cancer Res Ther; 2024 Jan; 20(1):285-288. PubMed ID: 38554335
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Assessing egfr-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.
    Chen WC; Cheng WC; Chen CL; Liao WC; Chen CH; Chen HJ; Tu CY; Lin CC; Hsia TC
    Cancer Med; 2024 Apr; 13(7):e7152. PubMed ID: 38549499
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study.
    Choi MG; Son GW; Choi MY; Jung JS; Rho JK; Ji W; Yoon BG; Jo JM; Kim YM; Ko DH; Lee JC; Choi CM
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38538093
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Patient Age and
    Maezawa Y; Taguchi M; Kawakami T; Inui T; Okauchi S; Numata T; Shiozawa T; Miyazaki K; Nakamura R; Iguchi K; Endo T; Sakamoto T; Satoh H; Hizawa N
    Anticancer Res; 2024 Apr; 44(4):1751-1757. PubMed ID: 38537995
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Biomarker Turnaround Times and Impact on treatment Decisions in Patients with Advanced Non-small cell lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional cancer Centre.
    Fleming KE; Hupel A; Mithoowani H; Lulic-Kuryllo T; Valdes M
    Curr Oncol; 2024 Mar; 31(3):1515-1528. PubMed ID: 38534948
    [No Abstract]    [Full Text] [Related]  


    of 376.